Eisai Europe Limited
Eisai Global Clinical Development
Eisai Manufacturing Limited
Eisai is a human health care (hhc) company which researches, manufactures and markets ethical pharmaceuticals. Eisai focuses its research efforts in two main therapeutic areas; Integrative Neuroscience including neurodegenerative disorders, neurology and psychiatric medicine and Integrative Oncology including oncotherapy and supportive-care treatment. The company employs more than 9,600 people worldwide, and reported consolidated sales of over £3.53 billion in FY2007, an increase of 8.9% year on year. Sales of Aricept, an Alzheimer`s disease treatment grew by 15.1% year on year and those of Pariet, a proton pump inhibitor increased by 0.9%. Other major products include Prialt for chronic pain, Zonegran and Inovelon for epilepsy and Rufinamide for LGS. Proactive investment in Research and Development (R&D) expenses came to £428 million.
Eisai Europe Limited (EEL) is the parent company for Eisai in Europe and reports to Eisai Company Limited, Japan – as does the R&D company Eisai London Laboratories Limited (ELL), based at UCL in London.
In the UK, two affiliate companies report to EEL, Eisai Limited (ESL) and Eisai Manufacturing Limited (EML). These three companies are located in Hatfield. In Hammersmith resides the European arm of clinical development, Eisai Global Clinical Development (EGC), until its relocation to Hatfield in early 2009.
The company`s main areas of focus are neurology and oncology:
In 1989, Eisai`s senior management team issued a "Commitment to Innovation." They asked the important question: "The world is changing; can you change along with them?"
The significance of Eisai`s commitment was its clear recognition that patients and their families are the most important participants in the healthcare process. Eisai takes pride in increasing the benefits to patients and their families while conducting its business.
Eisai`s commitment to innovation is embodied in its hhc (human health care) philosophy. To realize that mission Eisai conducts diverse patient-focused activities and the company`s philosophy is understood by every employee in Eisai, whether in Japan or overseas.
"We demonstrate our obligation to society, by identifying with the health care "participants", developing a response to their needs, verifying the social benefits of this response, and finally, making this response available to the world before anyone else. That is the hhc that Eisai aims to realize."
The European organisation is run by Eisai Europe Ltd., (EEL) which has its regional headquarters in Hatfield, UK. Eisai undertakes sales and marketing operations through its own distribution channels to 17 markets, including; the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands, and Luxembourg.
The UK affiliate, Eisai Ltd. (ESL), is based alongside the European organisation in Hatfield, and is responsible for pharmaceutical sales and marketing in the UK and the European led part of clinical research in the EU and ROW. In addition there is a research centre in University College London: Eisai London Research Laboratories Ltd.
European Knowledge Centre
In Hatfield, a £100m building programme is in progress for a new European hub holding the HQ, discovery research, clinical development and manufacturing as well as the UK operating company. Whilst the research centre in University College will remain, all other staff will be located at the Hatfield site once it is completed, by the end of Spring of 2009.